Plasmodium falciparum: Effect of chemical structure on efficacy and specificity of antisense oligonucleotides against malaria in vitro

Experimental Parasitology

Volumn 88, Issue 1, 1998, Pages 51-59

  Barker Jr , Robert H ^a,b   Metelev, Valeri ^b   Coakley, Aran ^a   Zamecnik, Paul ^b  

^a HYBRIDON INC   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ARTICLE; IN VITRO STUDY; MALARIA; PARASITE SURVIVAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALIA; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0031904411     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1006/expr.1998.4192     Document Type: Article

References (34)

1. Agrawal S., Iyer R. Modified oligonucleotides as therapeutic and diagnostic agents. Current Opinion in Biotechnology. 6:1995;12-19.
2. Agrawal S., Temsamani J., Galbraith W., Tang J. Pharmacokinetics of antisense oligonucleotides. Clinical Pharmacokinetics. 28:1995a;7-16.
3. Agrawal S., Zhang X., Lu Z., Zhao H., Tamburin J., Yan J., Cai H., Diasio R., Habus I., Jiang Z. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochemical Pharmacology. 50:1995b;571-576.
4. Barker R. H. Jr., Metelev V., Rapaport E., Zamecnik P. Inhibition of P. falciparum. Proceedings of the National Academy of Sciences USA. 93:1996;514-518.
5. Beaucage S. L. Oligodeoxyribonucleotide synthesis: Phosphoramidite approach. Protocols for Oligonucleotides and Analogs: Synthesis and Properties. 1993;Humana Press, Totowa. p. 33-61.
6. Beuria M. K., Das M. K. Dextran sulfate induced suppression ofPlasmodium berghei. Indian Journal of Experimental Biology. 29:1991;284-285.
7. Cazenave C., Stein C. A., Loreau N., Thuong N. T., Neckers L. M., Subasinghe C., Helene C., Cohen J. S., Toulme J.-J. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Research. 17:1989;4255-4273.
8. Clark D. L., Chrisey L. A., Campbell J. R., Davidson E. A. Non-sequence-specific antimalarial activity of oligodeoxynucleotides. Molecular and Biochemical Parasitology. 63:1994;129-134.
9. Ehrlich G., Patinkin D., Ginzberg D., Zakut H., Eckstein F., Soreq H. Use of partially phosphorothioated "antisense" oligonucleotides for sequence-dependent modulation of hematopoiesis in culture. Antisense Research and Development. 4:1994;173-183.
10. Fakler B., Herlitze S., Amthor B., Zenner H.-P., Ruppersberg J.-P. Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. Journal of Biological Chemistry. 269:1994;16187-16194.
11. Gao W.-Y., Han F.-S., Storm C., Egan W., Cheng Y.-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Molecular Pharmacology. 41:1992;223-229.
12. Gutteridge W. E., Trigg P. I. Incorporation of radioactive precursors into DNA and RNA ofPlasmodium knowlesi in vitro. Journal of Protozoology. 17:1970;89-96.
13. Iyer R. P., Egan W., Regan J. B., Beaucage S. L. 3H-1,2-Benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. Journal of the American Chemical Society. 112:1990;1253-1254.
14. Lisziewicz J., Sun D., Weichold F. F., Thierry A. R., Lusso P., Tang J., Gallo R. C., Agrawal S. Antisense oligodeoxynucleotide phosphorothioate complementary togag. Proceedings of the National Academy of Sciences USA. 91:1994;7942-7946.
15. Marshall E. Malaria: Serious setback for Patarroyo vaccine. Science. 273:1996;1652.
16. Metelev V., Agrawal S. Ion-exchange high-performance liquid chromatography of oligodeoxyribonucleotide phosphorothioates. Analytical Biochemistry. 200:1992;342-346.
17. Metelev V., Lisziewicz J., Agrawal S. Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-O. Bioorganic and Medicinal Chemistry Letters. 4:1994;2929-2934.
18. Monia B. P., Lesnik E. A., Gonzalez C., Lima W. F., McGee D., Guinosso C. J., Kawasaki A. M., Cook P. D., Freier S. M. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. Journal of Biological Chemistry. 268:1993;14514-14522.
19. Nosten F., Luxemburger C., Kyle D. E., Ballou W. R., Wittes J., Wah E., Chongsuphajaisiddhi T., Gordon D. M., White N. J., Sadorr J. C., Heppner D. G. Randomized double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. The Lancet. 348:1996;701-707.
20. Padmapriya A. A., Tang J., Agrawal S. Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates. Antisense Research and Development. 4:1994;185-199.
21. Ramasamy R., Kanagaratnam R., Misiura K., Rebowski G., Amerakoon R., Stec W. J. Anti-sense oligodeoxynucleoside phosphorothioates nonspecifically inhibit invasion of red blood cells by malaria parasites. Biochemical and Biophysical Research Communications. 218:1996;930-933.
22. Rapaport E., Misiura K., Agrawal S., Zamecnik P. Antimalarial activities of oligonucleotide phosphorothioates in chloroquine-resistantPlasmodium falciparum. Proceedings of the National Academy of Sciences USA. 89:1992;8577-8580.
23. 3. Molecular Pharmacology. 45:1994;932-943.
24. 3. Molecular Pharmacology. 47:1995;636-646.
25. Sproat B. S., Lamond A. I., Beijer B., Neuner P., Ryder U. Highly efficient chemical synthesis of 2′-O. Nucleic Acids Research. 17:1989;3373-3386.
26. Tang J., Temsamani J., Agrawal S. Self stabilized antisense oligodeoxynucleotide phosphorothioates: Properties and anti HIV activity. Nucleic Acids Research. 21:1993;2729-2735.
27. Trager W., Jensen J. B. Human malaria parasites in continuous culture. Science. 193:1976;673-675.
28. Van Dyke N., Tremblay G. C., Lantz C. H., Szustkiewicz C. The source of purines and pyrimidines inPlasmodium berghei. American Journal of Tropical Medicine and Hygiene. 19:1970;202-208.
29. Volkman S. K., Wilson C. M., Wirth D. F. Stage-specific transcripts ofPlasmodium falciparum pfmdr 1. Molecular and Biochemical Parasitology. 57:1993;203-212.
30. Bulletin of the World Health Organization. 70:1992;801-804.
31. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. Journal of Biochemical and Biophysical Methods. 13:1986;97-102.
32. Zhang R., Lu Z., Zhang X., Zhao H., Diasio R., Liu T., Jiang Z., Agrawal S. In vivo stability and disposition of a self stabilized oligodeoxynucleotide phosphorothioate in rats. Clinical Chemistry. 41:1995;836-843.
33. Zhang R., Lu Z., Zhao H., Zhang X., Diasio R., Habus I., Jiang Z., Iyer R., Yu D., Agrawal S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochemical Pharmacology. 50:1995;545-556.
34. Zugmaier G., Lippman M., Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor cell growth in animals. Journal of the National Cancer Institute. 84:1993;1716-1724.